May312022UncategorizedCategory: UncategorizedBy Charlotte Maddalena31 May 2022 Author: Charlotte Maddalena Post navigationPreviousPrevious post:ORPHELIA Pharma has been awarded a € 1 million grant from Bpifrance to develop a therapy for a rare form of epilepsyNextNext post:Progress of OREGA Biotech’s CD39 program: IPH5201 to advance into Phase 2 clinical trial in lung cancerRelated PostsORPHELIA Pharma will participate to the ANR 20239 May 2023ORPHELIA Pharma will participate to the SIOPe 20232 May 2023ORPHELIA Pharma Selects Tanner Pharma to Initiate Named Patient Program for KIMOZO®18 April 2023Jeremy BASTID, CEO of OREGA Biotech, will participate to the upcoming AACR annual meeting to be held on April 14-19 in Orlando, Florida17 April 2023ORPHELIA Pharma announces completion of patient recruitment for the TEMOkids clinical trial2 March 2023OREGA Biotech enters into a License Agreement with Genmab6 December 2022
Jeremy BASTID, CEO of OREGA Biotech, will participate to the upcoming AACR annual meeting to be held on April 14-19 in Orlando, Florida17 April 2023
ORPHELIA Pharma announces completion of patient recruitment for the TEMOkids clinical trial2 March 2023
